Skip to main content
Toggle navigation
Login
Home
Back
Favorite
0
Like
Facebook
Tweet
Session VI: Hepatobiliary Cancers
Debate: Optimal Second-Line Treatment in Hepatocellular Carcinoma? Tyrosine Kinase Inhibitors vs. IO - TYROSINE KINASE INHIBITORS
Thursday, April 21, 2022
3:03 PM – 3:11 PM
Debate Speaker(s)
Efrat Dotan, MD
Fox Chase Cancer Center